EngMab

EngMab, founded in 2013, focuses on T-cell bispecific antibodies, which can simultaneously attach to tumor cells and T-cell receptors, thereby triggering the activity of killing tumor cells. The company provides T-cell bispecific antibodies to remove malignant cells and serves customers in Switzerland.